Savolitinib (Synonyms: Volitinib; HMPL-504; AZD-6094)

Name: Savolitinib
Brand: MedChemExpress
SKU: HY-15959
Rating: 5.0 (7 reviews)

Cat. No.: HY-15959 Purity: 99.99% ee.: 98.12%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Savolitinib (AZD-6094) is a potent, highly selective, and orally bioavailable c-Met inhibitor with IC₅₀s of 5 nM and 3 nM for c-Met and p-Met, respectively. Savolitinib (AZD-6094) selectively binds to and inhibits the activation of c-Met in an ATP-competitive manner, and disrupts c-Met signal transduction pathways. Antineoplastic activity.

For research use only. We do not sell to patients.

CAS No. : 1313725-88-0

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 7 publication(s) in Google Scholar

7 Publications Citing Use of MCE Savolitinib

•bioRxiv. 2024 June 12.

PK/PD Analysis

Cell Proliferation/Viability Assay

: Savolitinib purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2026 Feb 3:e16660. [Abstract]; Compound testing in pancreatic cancer chip. Representative images 10 showing viability assessment by Hoechst33342 and EthD-2 staining after treatments with Savolitinib at indicated concentrations from 0.01 to 100 μM for 48 hours under 2D condition or after on-chip culture for 1 day or 7 days. Compound effects on BxPC-3 cell viability were analyzed using CellTiter-Glo ATP-assay or imaging detection (n=4).

: Savolitinib purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2023 Feb 21;4(2):100911. [Abstract]; Savolitinib (0.0097-10 μM; 96 h). Dose-effect curve of LCOs derived from the lymph node (LN) and pericardial effusion of P-60. IC₅₀ of osimertinib combined with Savolitinib were 1.32, 0.71, 0.25, and 0.24 μM in these four LCOs, respectively. Compared with IC₅₀ of Savolitinib (only performed in P-60-O3E and P-60-O4E, which were 11.59 and 17.61 μM).

: Savolitinib purchased from MedChemExpress. Usage Cited in: J Thorac Oncol. 2019 Oct;14(10):1753-1765. [Abstract]; Western blot analyses of transfected Ba/F3 cells in the presence of MET-TKIs at the indicated compounds (Savolitinib (1-100 nM), etc.) concentrations for 2 hours.

: Savolitinib purchased from MedChemExpress. Usage Cited in: J Sep Sci. 2017 Oct;40(19):3782-3791. [Abstract]; Concentration-time profiles in rat plasma after intravenous administration of Volitinib (Savolitinib; 8 h) or oral administration of Volitinib, when simultaneously (○) at the dose of 2 mg/kg.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

IC50: 5 nM (c-Met) and 3 nM (p-Met)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2	IC₅₀	>20 μM Compound: Savolitinib	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38086189]
L02	IC₅₀	>20 μM Compound: Savolitinib	Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38086189]
MHCC97H	IC₅₀	2.46 nM Compound: Savolitinib	Antiproliferative activity against human MHCC97H cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MHCC97H cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 38086189]
NCI-H441	IC₅₀	0.003 μM Compound: 28	Inhibition of c-Met autophosphorylation in human NCI-H441 cells for 1 hr by ELISA Inhibition of c-Met autophosphorylation in human NCI-H441 cells for 1 hr by ELISA	[PMID: 25148209]
NCI-H441	IC₅₀	0.006 μM Compound: 28	Antiproliferative activity against human NCI-H441 cells assessed as HGF-induced proliferation after 72 hrs by MTT assay Antiproliferative activity against human NCI-H441 cells assessed as HGF-induced proliferation after 72 hrs by MTT assay	[PMID: 25148209]

In Vivo

Savolitinib (Compound 28; 1-10.0 mg/kg; oral administration; daily; for 21 days; athymic nude mice) demonstrates dose-dependent tumor growth inhibition in a U87MG subcutaneous xenograft model. In addition, none of the mice in the dosing groups exhibits body weight loss during the experiment^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	U87MG xenograft model in athymic nude mice^[1]
Dosage:	1 mg/kg, 2.5 mg/kg and 10.0 mg/kg
Administration:	Oral administration; daily; for 21 days
Result:	Demonstrated dose-dependent tumor growth inhibition in a U87MG subcutaneous xenograft model.

Clinical Trial

Molecular Weight

345.36

Formula

C₁₇H₁₅N₉

CAS No.

1313725-88-0

Appearance

Solid

Color

Off-white to yellow

SMILES

CN1N=CC(C2=CN=C3C(N([C@H](C4=CN5C(C=C4)=NC=C5)C)N=N3)=N2)=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : ≥ 20.83 mg/mL (60.31 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.8955 mL	14.4776 mL	28.9553 mL
5 mM	0.5791 mL	2.8955 mL	5.7911 mL
10 mM	0.2896 mL	1.4478 mL	2.8955 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (6.02 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.08 mg/mL (6.02 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (6.02 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.99% ee.: 98.12%

Select Batch:

Data Sheet (281 KB) SDS (396 KB)

COA (257 KB) HNMR (266 KB) RP-HPLC (249 KB) NP-HPLC (88 KB) MS (69 KB)

Handling Instructions (2659 KB)

References

[1]. Jia H, et al. Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer. J Med Chem. 2014 Sep 25;57(18):7577-89. [Content Brief]

[2]. Gavine PR, et al. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models. Mol Oncol. 2015 Jan;9(1):323-33. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.8955 mL	14.4776 mL	28.9553 mL	72.3882 mL
	5 mM	0.5791 mL	2.8955 mL	5.7911 mL	14.4776 mL
	10 mM	0.2896 mL	1.4478 mL	2.8955 mL	7.2388 mL
	15 mM	0.1930 mL	0.9652 mL	1.9304 mL	4.8259 mL
	20 mM	0.1448 mL	0.7239 mL	1.4478 mL	3.6194 mL
	25 mM	0.1158 mL	0.5791 mL	1.1582 mL	2.8955 mL
	30 mM	0.0965 mL	0.4826 mL	0.9652 mL	2.4129 mL
	40 mM	0.0724 mL	0.3619 mL	0.7239 mL	1.8097 mL
	50 mM	0.0579 mL	0.2896 mL	0.5791 mL	1.4478 mL
	60 mM	0.0483 mL	0.2413 mL	0.4826 mL	1.2065 mL

Savolitinib Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Savolitinib1313725-88-0Volitinib HMPL-504 AZD-6094HMPL504HMPL 504HMPL-504AZD6094AZD 6094AZD-6094c-Met/HGFRInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Savolitinib (Synonyms: Volitinib; HMPL-504; AZD-6094)

Customer Review

Savolitinib Related Antibodies

7 Publications Citing Use of MCE Savolitinib

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Savolitinib Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report